Borderline CD30+ cutaneous lymphoproliferative disorder: Report of a case with expression of cytotoxic markers and response to clarithromycin

Journal of Cutaneous Pathology

Volumn 38, Issue 3, 2011, Pages 301-305

  Ponte, Pedro ^a,d   Serrão, Vasco ^a   Viana, Isabel ^b   Vale, Esmeralda ^b   João, Alexandre ^a   Cerroni, Lorenzo ^c  

^a HOSPITAL DOS CAPUCHOS   (Portugal)

^b Centro de Dermatologia Medico Cirurgica de Lisboa   (Portugal)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d HOSPITAL DE SANTO ANTÓNIO DOS CAPUCHOS   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CD30 ANTIGEN; CLARITHROMYCIN; TUMOR MARKER;

ADULT; ARTICLE; CASE REPORT; CUTANEOUS T CELL LYMPHOMA; HUMAN; MALE; METABOLISM; PATHOLOGY; SKIN TUMOR;

ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD30; CLARITHROMYCIN; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 78751655102     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2009.01476.x     Document Type: Article

References (20)

1. Willemze R, Jaffe ES, Burg G, et al., WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768.
2. Kempf W., CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol 2006; 33 (Suppl. 1): 58.
3. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al., Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653.
4. Kadin ME., Cutaneous Ki-1 lymphoma: pathology, immunology and clinical characteristics. Princess Takamatsu Symp 1987; 18: 187.
5. El Shabrawi-Caelen L, Kerl H, Cerroni L., Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C. Arch Dermatol 2004; 140: 441.
6. Querfeld C, Kuzel TM, Guitart J, Rosen ST., Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy. Oncology 2007; 21: 689.
7. Morikawa K, Oseko F, Morikawa S, Iwamoto K., Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. Antimicrob Agents Chemother 1994; 38: 2643.
8. Ichiyama T, Nishikawa M, Yoshitomi T, et al., Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 2001; 45: 44.
9. Ishimatsu Y, Kadota J, Iwashita T, et al., Macrolide antibiotics induce apoptosis of human peripheral lymphocytes in vitro. Int J Antimicrob Agents 2004; 24: 247.
10. Mizunoe S, Kadota J, Tokimatsu I, Kishi K, Nagai H, Nasu M., Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL. Int Immunopharmacol 2004; 4: 1201.
11. Mikasa K, Sawaki M, Kita E, et al., Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin. Chemotherapy 1997; 43: 288.
12. Hamada K, Mikasa K, Yunou Y, et al., Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer. Chemotherapy 2000; 46: 49.
13. Ohara T, Morishita T, Suzuki H, Masaoka T, Ishii H, Hibi T., Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. Anticancer Res 2004; 24: 3723.
14. Foss HD, Anagnostopoulos I, Araujo I, et al., Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 1996; 88: 4005.
15. Kummer JA, Vermeer MH, Dukers D, Meijer CJ, Willemze R., Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol 1997; 109: 636.
16. Boulland ML, Wechsler J, Bagot M, Pulford K, Kanavaros P, Gaulard P., Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins. Histopathology 2000; 36: 136.
17. Asano N, Suzuki R, Matsuo K, et al., Cytotoxic molecule expression is predictive of prognosis in Hodgkin's-like anaplastic large cell lymphoma. Histopathology 2007; 50: 705.
18. Vermeer MH, Geelen FA, Kummer JA, Meijer CJ, Willemze R., Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease. Am J Pathol 1999; 154: 1203.
19. Massone C, Crisman G, Kerl H, Cerroni L., The prognosis of early mycosis fungoides is not influenced by phenotype and T-cell clonality. Br J Dermatol 2008; 159: 881.
20. Cerroni L, Gatter K, Kerl H., Skin lymphoma-the illustrated guide, 3rd ed. Oxford: Wiley-Blackwell, 2009.